Nurix amends bylaws to comply with new universal proxy rules and DGCL updates

Nurix Therapeutics, Inc.

Revised advance notice bylaws require additional disclosures from nominating stockholders and restrict number of nominees to directors up for election.
Added compliance requirements for stockholders using universal proxy rules (Rule 14a-19), including certification and evidence submission 5 business days before meeting.
Updated meeting conduct: presiding officer may set extra attendance procedures; proxy card color must be non-white for soliciting stockholders.
Added emergency bylaw provision to allow board or committee quorum during situations preventing normal meeting requirements.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Nurix Therapeutics, Inc.: Amended and restated bylaws to update stockholder meeting procedures, advance notice requirements, universal proxy rules, and other provisions to conform to DGCL amendments and SEC universal proxy rules (effective 2022-12-15).

Change: bylaw amendment
Effective: 2022-12-15

Exact text from the filing

On December 15, 2022, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of Nurix Therapeutics, Inc. (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.

View on SEC.gov

Browse all governance changes →

Nurix Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-307328

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.